Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Urol. 2008 Jan;179(1):53-6. Epub 2007 Nov 13.

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.

Author information

  • 1Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. herrh@mskcc.org

Abstract

PURPOSE:

We review how the bacillus Calmette-Guerin vaccine evolved to become standard therapy for superficial bladder cancer.

MATERIALS AND METHODS:

We reviewed the historical literature describing the origin of the bacillus Calmette-Guerin vaccine as an anticancer agent and its singular success as the most effective immunotherapy used against a human neoplasm.

RESULTS:

The association between tuberculosis and cancer, and the demonstration that bacillus Calmette-Guerin invoked immunological reactivity, inhibiting tumor growth in experimental animal models, led to clinical trials showing that intravesical bacillus Calmette-Guerin eradicated and prevented recurrence of superficial bladder tumors.

CONCLUSIONS:

For the last 3 decades bacillus Calmette-Guerin therapy has remained the most effective local therapy for superficial bladder cancer, an outstanding example of successful translational medicine in urology.

Comment in

PMID:
17997439
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk